Moderna Looking To Price Its Coronavirus Vaccine At $50-$60, Significantly Above Rivals: FT

Moderna Inc MRNA is looking to price its COVID-19 vaccine significantly ahead of rivals in between $50 and $60 per course, the Financial Times reported Wednesday.

What Happened

The Massachusetts-based biotechnology company is considering pricing a single dose of the vaccine in the range of $25-$30, according to the Financial Times. This would be significantly higher than the $19.50 per dose implied price that Pfizer Inc PFE and its German partner BioNTech SE BNTX are charging the United States government, as part of their pre-order deal.

AstraZeneca plc AZN has entered into a deal with governments of the Netherlands, Germany, France, and Italy to supply its COVID-19 vaccine at $3 to $4 per dose, according to SVB Leerink analyst Geoffrey Porges. 

Moderna wants to charge early buyers, including the European Union, a price that is in high double-digit dollars per course, people in the know told the Financial Times.

The company’s pricing was causing “considerable concern and difficulties in negotiations, in view of the fact that other companies have pledged much lower prices,” said one of the British publication's sources.

Why It Matters

Moderna, Pfizer, and Merck & Co., Inc MRK all said at a Congressional hearing last week that they intended to make a profit on their respective vaccines.

AstraZeneca and Johnson & Johnson JNJ said they would not make a profit on the vaccines, should they get regulatory clearance, in the early phases of the pandemic.

Moderna on Sunday announced it would receive an additional $472 million in U.S. government funding, on top of a $483 million award it had already received, for late-stage clinical development of the vaccine. Earlier in the month, the government promised $1.6 billion in funding to Novavax, Inc NVAX.

Price Action

Moderna shares closed nearly 2% higher at $81.49 on Tuesday and added another 0.5% in the after-hours trading.

Photo by NIH on Flickr

Posted In: CoronavirusCovid-19Financial TimesGeoffrey PorgesUnited StatesvaccineBiotechGovernmentNewsHealth CareMediaGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.